Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024

Sartorius Stedim Biotech SA

/ Key word(s): Annual Results/Quarter Results

Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024

28-Jan-2025 / 07:04 CET/CEST

 

Aubagne, France | January 28, 2025

Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024
 

  • Sales revenue at 2,780 million euros, in constant currencies1 up +0.6 percent including non-organic contribution2, (reported: + 0.2 percent, organic1: – 0.7 percent in constant currencies)
  • Underlying EBITDA1 of 779 million euros, resulting margin at 28.0 percent; net profit of 175 million euros
  • 2024 revenue and profitability targets fully met
  • Order intake dynamics pick up significantly in second half of the year
  • Overall, cautiously positive outlook for 2025: profitable growth expected

In a challenging environment, Sartorius Stedim Biotech, a leading provider of innovative technologies for the manufacture of biologics, closed the fiscal year with a solid performance. With sales revenue at prior-year level and high profitability, according to preliminary figures, the company fully achieved its financial targets3 as adjusted at mid-year. For 2025, management expects profitable, moderate growth above market level.

“In 2024, Sartorius Stedim Biotech has successfully navigated the challenges that the entire life science industry continued to face: both inventory destocking and muted investment activities at customers continued for longer than anticipated. Under these conditions, Sartorius Stedim Biotech performed better than the market segment, proving its strong competitive position. While we shouldn’t focus too much on individual quarters, it’s encouraging to see an increasingly positive trend with business picking up significantly during the second half of the year and especially in the last quarter.,” said René Fáber, CEO of Sartorius Stedim Biotech. “The industry is gradually returning to its robust, structural growth trend. For 2025, however, we remain cautious and assume that market growth is still likely to be below the long-term average for now. Against this backdrop, we expect moderate revenue growth above market level and increasing profitability for our company.”

Business development1
In 2024, Sartorius Stedim Biotech generated sales revenue of 2,780 million euros, reaching the prior-year level. This corresponds to a slight growth of 0.6 percent in constant currencies1 (reported: + 0.2 percent; organic: – 0.7 percent in constant currencies1). Sales revenue includes a non-organic contribution2 of 2.4 percent. Development in the consumables business was particularly positive, as most biopharma customers are reaching their target inventory levels and are gradually returning to an order level that corresponds to their production activities. Sales revenue from products for advanced therapies also continued to grow at an above-average rate, while business with bioprocessing equipment remained muted. Order intake1 developed even better than revenue, increasing by a double-digit 12.9 percent in constant currencies (reported: + 12.3 percent).

As expected, business performance was particularly pronounced in the final quarter: between October and December, Sartorius Stedim Biotech achieved sales revenue of 751 million euros, an uptick of 6.1 percent in constant currencies1 (reported: + 6.3 percent) compared with the previous year, while order intake1 rose significantly by 23.8 percent in constant currencies.

Regional business performance varied in fiscal 2024. In the EMEA4 region, which accounts for around 42 percent of the Group’s business, sales revenue increased by 5.9 percent to 1,159 million euros. Despite the ongoing weakness of the Chinese market, the Asia | Pacific region grew by 4.0 percent to 639 million euros, thereby accounting for 23 percent of Group revenue. In the Americas region, on the other hand, sales revenue decreased by 6.7 percent to 982 million euros due to the continued subdued investment activity by customers. This corresponds to a share of 35 percent of the Group’s business.

The Group’s underlying EBITDA1 came in slightly below the prior year, down 0.8 percent to 779 million euros, with the resulting margin remaining at a high level of 28.0 percent (PY: 28.3 percent).

Underlying net profit1 totaled 338 million euros, compared with 386 million euros in the prior year, while net profit amounted to 175 million euros (PY: 310 million euros). Underlying earnings per share were 3.49 euros (PY: 4.19 euros) and earnings per share 1.81 euros (PY: 3.37 euros).

As of December 31, 2024, Sartorius Stedim Biotech employed 9,901 people worldwide, compared with 10,662 at the end of 2023.

With regard to its portfolio, Sartorius Stedim Biotech again expanded its product offering for biologics process development and manufacturing with a series of market launches. In addition to new products for customers working on cell and gene therapies, new products were launched in the areas of fluid management and filtration. Furthermore, partnering with a major customer, the Group developed a platform for continuous manufacturing which will allow for significantly higher efficiency and thus reduced resource consumption.

Key financial indicators
Sartorius Stedim Biotech’s key financial indicators remain at highly robust levels. Equity was 4,024 million euros as of December 31, 2024; the equity ratio1 increased significantly to 48.7 percent (December 31, 2023: 2,674 million euros and 34.6 percent, respectively), mainly as a result of the capital increase successfully completed at the beginning of February 2024.

Net operating cash flow was up by 9.2 percent to 815 million euros, compared with 746 million euros in the prior-year period, particularly due to the planned reduction of working capital1. Investments in research and the company’s global production infrastructure amounted to 340 million euros (PY: 474 million euros). The ratio of capital expenditures (capex) to sales revenue stood at 12.2 percent at year-end as projected (PY: 17.1 percent). Gross debt decreased to 2,869 million euros (December 31, 2023: 3,682 million euros), net debt to 2,191 million euros, and the ratio of net debt to underlying EBITDA1 to 2.8, as forecast (December 31, 2023: 3,565 million euros and 4.5, respectively).

Deliberately cautious outlook for fiscal 2025: profitable growth targeted
For fiscal 2025, Sartorius Stedim Biotech expects continuous demand recovery and growth in the life science market, albeit at a rate still below its long-term average. In this environment, the company intends to grow profitably above market level, and to achieve a moderate increase in sales revenue, which is likely to be driven primarily by recurring business with consumables. Based on the expected volume development, positive product mix effects and supported by the effects of the previous year’s efficiency program, the company forecasts that underlying EBITDA should increase over-proportionately compared with sales revenue. In 2025, Sartorius Stedim Biotech will continue its organic debt reduction course with a focus on working capital and managing investments.

The company will provide a quantitative forecast after the first quarter of 2025.

1 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving comparability of business performance over time and within the industry.
 

  • Constant currencies: figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous period
  • Organic: organic growth figures exclude the impact from changes in exchange rates and changes in the scope of consolidation
  • Order intake: all customer orders contractually concluded and booked during the respective reporting period
  • Underlying EBITDA: earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items
  • Underlying net profit: profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, and based on the normalized financial result and the normalized tax rate
  • Equity ratio: equity in relation to the balance sheet total
  • Ratio of net debt to underlying EBITDA: quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period
  • Working capital: sum of inventories and trade receivables

2 Acquisition of Polyplus
3 Forecast for fiscal year 2024 as of July 2024
4 EMEA = Europe, Middle East, Africa

This media release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.
Management points out that dynamics and volatilities in the industry have increased significantly in recent years. In addition, uncertainties due to the changed geopolitical situation, such as the emerging decoupling tendencies of various countries, are playing a greater role. This results in higher uncertainty when forecasting business figures.

Conference call
René Fáber, CEO of the Sartorius Stedim Biotech Group, will discuss the company’s business results with analysts and investors in a conference call at 1.00 p.m. CET on January 28, 2025.
Register here: Conference Call on the Preliminary Results 2024



Financial calendar
February 17, 2025          Publication of Annual Report
March 25, 2025                Annual Shareholders’ Meeting
April 16, 2025                   Publication of the first quarter results January to March 2025
July 22, 2025                    Publication of the half-year results January to June 2025
October 16, 2025            Publication of the nine-month results January to September 2025

Preliminary key figures for the full year of 2024
 

in millions of € unless otherwise specified 2024 2023 Δ in % Δ in % cc1
Order Intake and Sales Revenue        
Order intake² 2,781.6 2,476.1 12.3 12.9
Sales revenue 2,780.0 2,775.5 0.2 0.6
  • EMEA3
1,159.0 1,093.4 6.0 5.9
  • Americas3
982.0 1,054.0 -6.8 -6.7
  • Asia | Pacific3
639.0 628.1 1.7 4.0
Results        
EBITDA4 779.0 785.4 -0.8  
EBITDA margin4 in % 28.0 28.3 -0.3pp  
Underlying net profit5 337.5 385.9 -12.5  
Underlying earnings per share5 in € 3.49 4.19 – 16.7  
Net profit6 | 7 175.1 310.3 -43.6  
Earnings per share6 | 7 in € 1.81 3.37 -46.3  
         

1 cc = constant currency: Figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous period
2 All customer orders contractually concluded and booked during the respective reporting period
3 According to customer location
4 Earnings before interest, taxes, depreciation and amortization, and adjusted for extraordinary items
5 Profit for the period after non-controlling interest, adjusted for extraordinary items, and amortization, as well as based on the normalized financial result and the normalized tax rate 
6 After non-controlling interest
7 The previous year’s figures have been revised due to finalization of the purchase price allocation for the acquisition of Polyplus                      



Reconciliation of alternative performance measures

Reconciliation between EBIT and underlying EBITDA

In millions of €
unless otherwise specified
2024 2023
EBIT (operating result) 370.6 449.5
Extraordinary items 106.7 99.1
Depreciation and amortization 301.7 236.8
Underlying EBITDA 779.0 785.4

The previous year’s figures have been revised due to finalization of the purchase price allocation for Polyplus.
Reconciliation between EBIT and underlying net result

In millions of €,
unless otherwise specified
2024 2023
EBIT (operating result) 370.6 449.5
Extraordinary items 106.7 99.1
Amortization | IFRS 3 116.7 90.3
Normalized financial result1 -133.2 -114.1
Normalized income tax (26%)2 -119.8 -136.4
Underlying net result after taxes 340.9 388.3
Non-controlling interest -3.4 -2.4
Underlying net result after taxes and non-controlling interest 337.5 385.9
Underlying earnings per share (in €) 3.49 4.19

1 Financial result excluding fair value adjustments of hedging instruments and currency effects relating to financing activities and change in valuation of earn-out liability
2 Normalized income tax based on the underlying profit before taxes and non-cash amortization

The previous year’s figures have been revised due to finalization of the purchase price allocation for the acquisition of Polyplus                      

Calculation of net debt and ratio of net debt to underlying EBITDA

in millions of €
unless otherwise specified
2024 2023
Gross debt 2,869.5 3,681.8
–  Cash & cash equivalents 678.9 116.6
Net debt 2,190.6 3,565.2
     
Underlying EBITDA (12 months) 779.0 785.4
+ Pro forma EBITDA from acquisitions (12 months) 0.0 14.7
Pro forma underlying EBITDA (12 months) 779.0 800.0
Ratio of net debt to underlying EBITDA 2.8 4.5

Calculation of the capital expenditures ratio

in millions of €
unless otherwise specified
2024 2023
Sales revenue 2,780.0 2,775.5
Capital expenditures 339.8 473.6
Capital expenditures as % of sales revenue 12.2 17.1

A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros, according to preliminary figures. Currently, more than 9,900 employees are working for customers around the globe.

Visit our newsroom and follow us on LinkedIn.

Contact
Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
 


Attachment

File: Media Release Sartorius Stedim Biotech Preliminary Unaudited Results 2024


Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


show this

Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase in Sales and Adjusted EBIT

Eckert & Ziegler SE / Key word(s): Preliminary Results

Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase in Sales and Adjusted EBIT

27-Jan-2025 / 18:55 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Financial Year 2024 (preliminary):

  • Sales of around EUR 295 million (previous year:  EUR 246.1 million)
  • EBIT before special items of around EUR 66 million (previous year: EUR 46.9 million)
  • Net Income of around EUR 33 million (previous year: EUR 26.3 million)

Berlin, 27 January 2025. According to preliminary, unaudited figures, Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of around EUR 295 million and an adjusted EBIT of around EUR 66 million in the 2024 financial year. Sales increased by 20% compared to the previous year. Adjusted EBIT is even 41% higher than in the previous year and thus above the raised forecast for FY 2024 issued on 22 November 2024. Net profit (from continued and discontinued operations), which is only reported here for comparison purposes, rose to around EUR 33 million (previous year: EUR 26.3 million).

The guidance for the 2025 financial year will be published on 27 March 2025 together with the complete, audited annual financial statements for 2024.

Contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 

End of Inside Information


27-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Invitation to Straumann Group’s FYR 2024 analysts and media conference at Straumann Group Headquarters

Straumann Holding AG

/ Key word(s): Quarter Results/Sales Result

Invitation to Straumann Group’s FYR 2024 analysts and media conference at Straumann Group Headquarters

27.01.2025 / 15:28 CET/CEST

Date: Wednesday, February 19, 2025

Program:

09:30 a.m. CET Door opening & welcome coffee

10:00 – 11:00 a.m. CET Presentation, questions and answers

Location:

Straumann Group headquarters

Peter Merian-Weg 12

4052 Basel, Switzerland

The Straumann Group Management will review the operational performance of the fiscal year 2024, provide an outlook, and answer questions from investors, financial analysts and journalists. The conference and Q&A session will be held in English.

Please send your response no later than February 14, 2025

Straumann Group

Corporate Communications & Investor Relations

E-Mail: investor.relations@straumann.com

There will also be a live audio webcast that can be accessed via www.straumann-group.com/webcast, and a recording will be available afterwards.

With kind regards

Straumann Group Corporate Communications & Investor Relations


End of Media Release


show this

Invitation to Straumann Group’s 2024 full-year results webcast

Straumann Holding AG

/ Key word(s): Quarter Results/Sales Result

Invitation to Straumann Group’s 2024 full-year results webcast

27.01.2025 / 15:27 CET/CEST

Date: Wednesday, February 19th, 2025

Time: 10:00 – 11:00 a.m. CET

Straumann Group will publish its 2024 full-year results on Wednesday, February 19th, 2025, at approximately 7:00 a.m. CET through the usual channels.

The live audio webcast is aimed at investors, financial analysts and journalists. The Group’s top management will review the performance and answer participants’ questions. The presentation and Q&A session will be held in English.

The webcast can be accessed via www.straumann-group.com/webcast, and a recording will be available afterwards.

If you intend to ask a question during the Q&A, we kindly ask you to pre-register for the conference call through this link. We also recommend that you download the presentation file in advance using the direct link in the media release on www.straumann-group.com before joining the conference call.

With kind regards

Straumann Group Corporate Communications & Investor Relations


End of Media Release


show this

Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million

Pentixapharm Holding AG / Key word(s): Preliminary Results

Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million

24-Jan-2025 / 17:00 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Berlin, January 24, 2025 – According to initial preliminary evaluations, Pentixapharm Holding AG will close the 2024 financial year with a loss of around EUR 14 million. In addition to the operating loss of EUR 7 million, the total also includes non-cash write-downs for intangible assets. They result from the termination of development projects at the subsidiary Myelo Therapeutics GmbH, which were previously mainly financed by contracts from various US government agencies. According to the opinion of the Management Board and Supervisory Board, the recent change in the U.S. administration has significantly worsened the conditions for amortization, as previous funding programs have been canceled or not extended.

The annual report for 2024 with details of the development project will be published on April 15, 2025.

For more information, please contact:

Pentixapharm Holding AG
Phillip Eckert, Investor Relations
ir@pentixapharm.com
Tel. +49 30 94893232
www.pentixapharm.com

End of Inside Information


Information and Explanation of the Issuer to this announcement:

About Pentixapharm

Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds as well as early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.


24-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Significant progress in all operating areas; stable fourth quarter leads to annual sales of EUR 12.2 million (+6%)

EQS-News: aap Implantate AG

/ Key word(s): Sales Result

Significant progress in all operating areas; stable fourth quarter leads to annual sales of EUR 12.2 million (+6%)

24.01.2025 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

aap Implantate AG (“aap” or “Company”) informs that with the end of a stable fourth quarter a preliminary sales growth of 6.3% compared to the previous year could be achieved. Growth was achieved in all regions except the USA. The investment in further aap systems to equip customers characterized the product mix, so that the company sees a good basis for further growth. In the USA, sales decreased due to the restructuring carried out in the fourth quarter of 2023 (minus 19% for the year as a whole) and recovered in the last quarter of 2024 to -11% compared to the same quarter of the previous year.

Turnover FY/2024

in TEUR FY/2024 FY/2023 Change
Trauma
 EMEA (=Europe, Middle East, Africa)
North America (=USA)
LATAM (= Latin America)
APAC (=Asia-Pacific)
 
6.329
2.874
2.534
   466
 
   5.475
   3.567
   2.083
      352
 
16%
-19%
22%
32%
Turnover 12,203 11.477 6%

 

aap made significant progress in 2024:

  • Due to the very good progress of the study with the antibacterial surface-treated implants, patient recruitment was completed ahead of schedule after consultation with the BfArM and the Ethics Committee;
  • The successful completion of the first MDR audit in September and the positive MDR assessment of the first product file pave the way for a foreseeable conclusion to the MDR certification process;
  • Approvals in new markets, primarily in the APAC region, provide a good basis for future growth;
  • Equity was significantly strengthened through various capital measures
  • the operating cash flow was improved by the 2023 restructuring, among other things

The company will provide information on the outlook for the 2025 financial year and the management agenda in a separate announcement.

The sales figures contained in this press release are preliminary figures as of December 31, 2024, which are subject to change until final publication. aap plans to announce the final, audited results for the financial year 2024 at the end of April as part of the consolidated annual financial report 2024.

 

 

——————————————————————————————————————————————-

aap Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German stock exchanges –

 

 

About aap Implantate AG

aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, produces and markets products for traumatology. The IP-protected portfolio includes the innovative anatomical plate system LOQTEQ® and a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while internationally it primarily uses a broad network of distributors in around 25 countries. In the United States, the company and its subsidiary aap Implants Inc. rely on a sales strategy via distribution agents and selective direct sales. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.

 

The figures presented in this press release may be subject to technical rounding differences that do not affect the overall picture.

 

Forward-looking statements

This release may contain forward-looking statements that are based on the current expectations, assumptions and forecasts of the Executive Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of the future developments and results mentioned therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual results, financial situation, development or performance of the company and the estimates given here. These factors include those that aap has described in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We assume no obligation to update the forward-looking statements made in this release or to adapt them to future events or developments.

 

If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo; Chairman of the Management Board/ CEO; Lorenzweg 5; 12099 Berlin

Phone: +49 (0)30 75019 – 141; Fax: +49 (0)30 75019 – 290; Email: r.digirolamo@aap.de


24.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

EQS-News: ABIVAX

/ Key word(s): Study results

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

23.01.2025 / 22:05 CET/CEST

The issuer is solely responsible for the content of this announcement.

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress 

PARIS, France – January 23, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced that seven scientific abstracts on its lead drug candidate, obefazimod, [an investigational, orally administered, once-daily small molecule] in clinical development for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at The European Crohn’s and Colitis Organization’s (ECCO’s) 20th Annual Congress as part of scientific exchange, taking place February 19-22, 2025, in Berlin, Germany.

“With 7 abstracts accepted for presentation at ECCO 2025, we look forward to our continued exchange with the inflammatory bowel disease community around the emerging clinical profile of obefazimod,” said Fabio Cataldi, MD, Chief Medical Officer of Abivax

For more information, see congress details on the ECCO website, and visit the Abivax booth at the ECCO exhibitor hall (booth #30).

Obefazimod data to be presented:

Presentation Title Session Presenter Presentation/ Session Number Session Hall Date and Time (EDT)
Oral Presentation
“Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QD”
 
Digital Oral Presentation Session 6
 
Prof. Silvio Danese, MD, PhD
 
Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital

 

 Clinical Trials III
 
Hall A7
 
Friday, February 21, 2025
 
8:42am to 8:48am
 
Poster Presentations
“Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study”
 
Guided Poster Session
 
Fernando Magro, MD, PhD
 
President-Elect of ECCO. Head of the Department of Clinical Pharmacology and Professor of Pharmacology and Therapeutics at University Hospital São João in Porto, Portugal
 
 Poster number: P0636
 
 Hall 2.2
 
Friday, February 21, 2025
 
12:40pm to 1:40pm
 
“Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis”
 
Guided Poster Session
 
Prof. Séverine Vermeire, MD, PhD
 
Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study programs conducted and ongoing with obefazimod in UC
 
 Poster number: P0813
 
 Hall 2.2
 
Friday, February 21, 2025

12:40pm to 1:40pm
 

“Health-related quality of life (HRQOL) in patients with ulcerative colitis (UC) treated with obefazimod: the phase 2 open-label maintenance study”
 
Guided Poster Session
 
Jennifer Fine, ScD
Head of HEOR, Abivax S. A
 
 Poster number: P0840
 
 Hall 2.2
 
Friday, February 21, 2025
 
12:40pm to 1:40pm
 
“Efficacy and safety of obefazimod for the fourth and sixth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): 2-year interim analysis after dose de-escalation to 25 mg”
 
Guided Poster Session
 
Prof. Silvio Danese, MD, PhD
 
Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital
 
  Hall 2.2
 
Friday, February 21, 2025
 
12:40pm to 1:40pm
 
“Long-term treatment patterns, dose escalation, and steroid use among patients with moderate-to-severe ulcerative colitis using advanced therapies: 3 years of continuous follow-up using IQVIA PharMetrics Plus database”
 
Guided Poster Session
 
Prof. Parambir S. Dulai, M.D.
 
Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois
 
  Hall 2.2
 
Friday, February 21, 2025
 
12:40pm to 1:40pm
 
“Synergistic reduction of inflammatory cytokines with obefazimod and etrasimod in combination treatment vs. either monotherapy in a mouse model of inflammatory bowel disease” Guided Poster Session Didier Scherrer, PhD
Chief Scientific Officer
Abivax S.A.
  Hall 2.2 Friday, February 21, 2025
 
12:40pm to 1:40pm

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878


23.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors

Galenica AG

/ Key word(s): Personnel

Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors

23.01.2025 / 07:00 CET/CEST

Press release

Nadine Balkanyi-Nordmann, an experienced legal, compliance and governance expert, will be recommended for election as a member of the Board of Directors at the next Annual General Meeting of the Galenica Group.

At the upcoming Annual General Meeting on 10 April 2025, a new member will be proposed to shareholders for election to the Galenica Board of Directors: Nadine Balkanyi-Nordmann (born in 1972), a recognised leader and expert in various fields of law. This would restore the Board of Directors to seven members.

 

Chairman of the Galenica Board of Directors Markus Neuhaus comments on the nomination: “I am pleased to propose Nadine Balkanyi-Nordmann for election as a new member on behalf of the entire Board of Directors. She is a respected expert in Switzerland in the field of administrative law and risk management and has extensive knowledge of conducting administrative investigations in the public sector, implementing new regulations and developing compliance programmes. In addition, she is a distinguished lawyer and has in-depth knowledge of the healthcare sector.”

 

Leading expert in financial services and healthcare

Nadine Balkanyi-Nordmann is the founder and CEO of Lexperience AG. She has worked for prominent law firms and major financial institutions and has trained at several international institutions. Following her time practising law at Walder Wyss & Partners in Zurich, the Swiss attorney held management positions for various banks such as UBS, GE Capital Bank and BNP Paribas in Asia, America and Switzerland.

 

Nadine Balkanyi-Nordmann studied law at the University of Zurich and was admitted to the Zurich bar. She also holds an LL.M. (Master of Laws) from Hong Kong University. She has extensive knowledge of corporate governance and conducting administrative investigations in the public sector. She is to reinforce the Board of Directors of the Galenica Group with her expertise in integrating ESG criteria when it comes to listed companies and implementing new regulatory requirements.

 

Nadine Balkanyi-Nordmann will not stand for re-election to the Board of Directors of Sanitas in 2025, a position she has held since 2013.

 

Photo of Nadine Balkanyi-Nordmann

Dates for the diary

11 March 2025

Publication of Annual Results of the Galenica Group 2024

10 April 2025

Annual General Meeting of Galenica Ltd.

22 May 2025 Galenica Group sales update

7 August 2025

Publication of Galenica Group half-year results 2025

 

For further information, please contact:

 

Media Relations:
Tel. +41 58 852 85 17
E-Mail:
media@galenica.com
 

Welcome to the Galenica network!
Over 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally. 

Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com.


End of Media Release


show this

Galenica reports strong sales growth once again

Galenica AG / Key word(s): Development of Sales

23-Jan-2025 / 06:45 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Press release
Ad hoc announcement pursuant to Art. 53 LR

Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).

Following a solid increase in sales of 2.6% in the first half of 2024, Galenica again posted significantly stronger growth of +6.7% in the second half of 2024. Market share gains in the wholesale business with doctors and pharmacies contributed significantly to the increase in sales. In addition to acquisitions, the main growth driver in the pharmacy business was strong organic growth in sales of prescription-only medications. In addition, the second half of the year had two more sales days than in the prior-year period, which boosted growth in this half-year period by an estimated +1.6%. Due to the leap year, 2024 as a whole had one more sales day than in the previous year, which corresponds to an additional growth effect of around +0.4%.

 

By contrast, a mild flu outbreak and a low occurrence of colds in the fourth quarter of 2024 weakened sales growth, particularly in the “Products & Brands” sector. Significant additional sales of generics and biosimilars also continued to dampen growth. The generics substitution rate of Galenica pharmacies increased by 4.0% on average in 2024 to a high 79.2% (75.2% at the end of December 2023).

 

Guidance for 2024 annual results confirmed

Galenica confirms its guidance for the 2024 annual results projecting EBIT1 growth between 8% and 11% and a dividend at least at the previous year’s level.

 

Net sales of the Galenica Group January – December 2024

 

(in million CHF)

2024

2023

Change

Products & Care segment

 1,700.2

 1,635.6

3.9%

Retail (B2C)

 1,442.0

 1,385.6

4.1%

Local Pharmacies

 1,365.1

 1,306.9

4.4%

Pharmacies at Home

 77.3

 78.9

-2.1%

Professionals (B2B)

 268.2

 256.1

4.7%

Products & Brands

 183.4

 177.1

3.5%

Services for Professionals

 84.8

 78.9

7.5%

Logistics & IT segment

 3,240.7

 3,077.0

5.3%

Wholesale

 3,104.5

 2,952.7

5.1%

Logistics & IT Services

 157.2

 144.0

9.2%

Corporate and eliminations

 -1,019.2

 -966.6

 

Galenica Group

 3,921.7

 3,746.0

4.7%

 

1 Excluding the effects of IFRS 16 and IAS 19

 

PRODUCTS & CARE SEGMENT

 

The “Products & Care” segment achieved net sales of CHF 1,700.2 million (+3.9%) in the 2024 financial year. Of this, CHF 1,442.0 million (+4.1%) was attributable to “Retail” (B2C), with “Local Pharmacies” contributing CHF 1,365.1 million (+4.4%, excluding Coop Vitality) and “Pharmacies at Home” accounting for CHF 77.3 million (-2.1%, excluding Mediservice).

 

“Professionals” (B2B) increased sales to CHF 268.2 million (+4.7%), with “Products & Brands” contributing CHF 183.4 million (+3.5%) and “Services for Professionals” CHF 84.8 million (+7.5%).

 

Retail (B2C)

  • The pharmacy network (excluding Coop Vitality Coop) continued to evolve dynamically: Twelve pharmacies were acquired, two new pharmacies were opened and four were closed or merged with other locations. The expansion effect on sales growth in “Local Pharmacies” therefore amounted to +1.7%.
  • Adjusted for this expansion effect, Galenica pharmacies grew organically by 2.7% thanks to high demand for prescription-only medications.
  • Compared to the previous year, demand for vaccinations in Galenica pharmacies increased by 20% (excluding COVID-19 vaccinations).
  • Around 193,000 customers made use of the healthcare services and advice offered by Galenica pharmacies in 2024, 39% more than in the previous year.
  • The “Pharmacies at Home” sector experienced a slight decline due to the streamlining of various services. The largest business, “Bichsel HomeCare”, continued to grow steadily.

By way of comparison

  • Sales of medications from bricks-and-mortar pharmacies in Switzerland (prescription-only [Rx] and OTC products) grew by 3.5% in the reporting period (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
  • Sales of medications from mail-order pharmacies in Switzerland (prescription-only [Rx] and OTC products) declined year-on-year by -2.9% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
  • The non-drugs segment of the Consumer Healthcare market also contracted by -0.8% in the period under review (IQVIA, Consumer Health Market Switzerland, YTD December 2024, nutrition, personal care, patient care, excluding OTC).

Professionals (B2B)

  • Verfora continued to grow in 2024 and expanded its market position. Organic growth in “Products & Brands”, excluding the expansion effect (+0.7%) attributable to the acquisition of Padma in 2023, amounted to 2.8%.
  • Verfora’s export business showed very positive organic growth, with an increase of 15.1%. This pleasing result was driven by higher demand for Verfora products such as Perskindol® in Asia, and earlier product deliveries abroad compared to the previous year.
  • Due to a reduction in inventories in the market combined with a mild flu outbreak in the fourth quarter of 2024, Verfora’s Swiss business saw a slight organic decline of -0.2%. At 4.2%, sales of Verfora products in the pharmacy and drugstore market grew faster than the overall market (IQVIA, Consumer Health Market Switzerland, YTD December 2024), enabling further market share to be gained.
  • The growth drivers in “Services for Professionals” (+7.5%) were once again Lifestage Solutions, and Medifilm in the business with care homes and home care organisations.

By way of comparison

  • The consumer healthcare market grew by 1.1% year-on-year (IQVIA, Consumer Health Market Switzerland, YTD December 2024).
     

LOGISTICS & IT SEGMENT

 

The “Logistics & IT” segment achieved net sales of CHF 3,240.7 million (+5.3%) in the 2024 financial year.
Of this, CHF 3,104.5 million (+5.1%) was attributable to “Wholesale” and CHF 157.2 million (+9.2%) to “Logistics &
IT Services”.

 

Highlights

  • The pharmacy customer segment grew by 4.0%, outperforming the market.
  • At 7.8%, the greatest growth was achieved in the physicians segment, which enabled market share to be gained.
  • HCI Solutions also performed well. By the end of December, around 369 million CDS checks had been carried out (+33%), an important contribution to patient safety.

 

By way of comparison

  • The overall pharmaceutical market grew by 3.5% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
  • The physicians segment grew by 5.7% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
  • The pharmacy segment grew by 2.9% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).

 

Additional information on sales figures and further information can be found in our sales presentation.

 

Upcoming dates

11 March 2025

Publication of Annual Results 2024 of the Galenica Group

10 April 2025

Annual General Meeting of Galenica Ltd.

22 May 2025

Galenica Group sales update

7 August 2025

Publication of Galenica Group half-year results 2025

 

For further information, please contact:

 

Media Relations:
Iris Müller, Chief Communications Officer
Tel. +41 58 852 85 17
E-Mail:
media@galenica.com
Investor Relations:
Julian Fiessinger, CFO
Tel. +41 58 852 85 31
E-Mail:
investors@galenica.com

Welcome to the Galenica network!
Over 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally. 

Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com.


End of Inside Information


show this

Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014: Purchase of own shares – final notice

EQS-News: Drägerwerk AG & Co. KGaA

/ Key word(s): Miscellaneous

Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014: Purchase of own shares – final notice

22.01.2025 / 14:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014: Purchase of own shares – final notice

The share buyback of Drägerwerk AG & Co. KGaA (“Dräger”), which had begun on October 7, 2024, was completed on January 20, 2025. A total of 77,316 preferred shares were bought back during this period. The start of the buyback was announced on October 1, 2024. On November 22, 2024, Dräger announced the extension of the buyback.

The acquisition of the preferred shares served the purpose of fulfilling obligations relating to an employee stock program within the meaning of article 5, paragraph 2 (c) of the Regulation (EU) No 596/2014. The Executive Board did not participate in the program due to the new regulations on share-based remuneration.

A bank mandated by Dräger conducted the buyback of the Dräger preference shares exclusively on a stock exchange.

In accordance with Art. 5 (1) and (3) of the Regulation (EU) No 596/2014 and Art. 2 (2) and (3) of the Delegated Regulation (EU) 2016/1052, information about the transactions is available on the Company’s website (www.draeger.com) in the Investor Relations section (www.draeger.com/en_corp/Investor-Relations/Share).

Lübeck, Germany, January 22, 2025

Executive Board
Drägerwerk Verwaltungs AG, acting as the general partner of
Drägerwerk AG & Co. KGaA

Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com


22.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this